<SEC-DOCUMENT>0001274737-21-000042.txt : 20210511
<SEC-HEADER>0001274737-21-000042.hdr.sgml : 20210511
<ACCEPTANCE-DATETIME>20210511160629
ACCESSION NUMBER:		0001274737-21-000042
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210511
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210511
DATE AS OF CHANGE:		20210511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		21911282

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xgn8-kxq121earningsrelease.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i57578eba4b3d4faca304b83f9147c056_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM 8-K </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported)&#58; May 11, 2021 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">EXAGEN INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:32.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.601%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">001-39049</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20-0434866</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of incorporation or organization)</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Commission</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Number)</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</font></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1261 Liberty Way </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vista, CA 92081 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code) </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(760) 560-1501 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, include area code) </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N&#47;A </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report) </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58; </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:2.331%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.163%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:95.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act&#58; </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:32.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.601%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Symbol(s)</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">on which registered</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock, par value $0.001 per share</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">XGN</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Nasdaq Global Market</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746; </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744; </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2021, Exagen Inc. (the &#8220;Company&#8221;) reported its financial results for the three months ended March 31, 2021. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.103%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exagen1q21earningspressrel.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release dated May 11, 2021</a></font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.220%"><tr><td style="width:1.0%"></td><td style="width:43.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.652%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.947%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2021</font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exagen1q21earningspressrel.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibf26c0325a5f4f0cbb59d835e5ae069c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><img alt="image_01.jpg" src="image_01.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:171px"></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:125%">Exagen Inc. Reports First Quarter 2021 Results</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Quarterly Records&#58; AVISE&#174; CTD Volumes, Ordering Healthcare Providers and Adopters</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">May 11, 2021</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">SAN DIEGO &#8211; Exagen Inc. (Nasdaq&#58; XGN),&#160;a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March&#160;31, 2021.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">First Quarter Highlights&#58;</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Generated total revenue of $10.6 million for the quarter ended March&#160;31, 2021.</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Delivered a record 29,029 flagship AVISE&#174; CTD tests, including AVISE&#174; Lupus, in the first quarter 2021. </font></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Record number of ordering healthcare providers totaling 1,763 in the first quarter, including a record 659 adopters, and sequential quarterly retention rate of approximately 99% among adopting healthcare providers from the prior quarter.</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Expanded sales force to 60 representatives to cover 63 territories as of March&#160;31, 2021, and launched inside sales team to focus on covering white space and furthering our reach and frequency with rheumatologists.</font></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Completed follow-on public offering of common stock in March resulting in aggregate net proceeds to the company of $64.7 million to focus on growth initiatives and working capital&#59; total cash and cash equivalents were approximately $118.1 million at quarter-end.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;We are very pleased with our continued performance in the first quarter of 2021. With our expanded sales force and over 67 million lives in-network, we continue to build on our momentum with March recognized as an all-time record volume month,&#34; said Ron Rocca, President and Chief Executive Officer of Exagen. &#34;Throughout the quarter we continued to position Exagen as a leading autoimmune testing solutions company that places patient care first. With the additional capital raised in the first quarter, we are making further investments in our world-class R&#38;D organization and focusing on new products that will improve patient care, improve efficiencies and build upon our already robust portfolio.&#34;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">First Quarter 2021 Financial Results&#160;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Revenue for the three months ended March&#160;31, 2021 was $10.6 million, compared with $9.6 million in the first quarter of 2020. Testing revenue was $10.3 million for the first quarter of 2021, compared to $9.6 million in the first quarter of 2020, due to increased testing volumes. Our SIMPONI&#174; co-promotion </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">efforts contributed $0.3 million in the first quarter of 2021, compared to no co-promotion revenue in the first quarter of 2020. Gross margin was 56% in the first quarter of 2021 compared to 53% in the first quarter of 2020, benefiting from an increase in SIMPONI&#174; revenues and a decrease in royalty costs.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Operating expenses were $16.2 million in the first quarter of 2021, compared with $14.8 million in the first quarter of 2020, due to increases in employee related expenses from headcount growth, including stock-based compensation, and research and development expenses.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For the first quarter of 2021, net loss was $6.2 million, compared to a net loss of $5.6 million for the first quarter of 2020.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Cash and cash equivalents were approximately $118.1 million as of March&#160;31, 2021.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2021 Guidance&#160;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">For the full year 2021, Exagen reaffirms its prior guidance and expects revenue to be in the range of $47 million to $49 million.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Conference Call</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">A conference call to review first quarter 2021 financial results and to provide a business update is scheduled for today May 11, 2021 at 4&#58;30 PM Eastern Time (1&#58;30 PM Pacific Time). Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Additionally, a link to a live webcast of the call will be available in the Investor Relations section of Exagen's website at http&#58;&#47;&#47;investors.exagen.com.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Participants are asked to join a few minutes prior to the call to register for the event. A replay of the conference call will be available until Tuesday, May 18, 2021 at 11&#58;59 PM Eastern Time (8&#58;59 PM Pacific Time). Interested parties may access the replay by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13718936. A link to the replay of the webcast will also be available in the investor relations section of Exagen's website.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Exagen</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE&#174; brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen&#8217;s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For more information, please visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;text-decoration:underline">www.Exagen.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Forward Looking Statements</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company&#8217;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding&#58; the potential benefit of the company's testing products and promoted therapeutic for patients and physicians in autoimmune disease treatment&#59; the expected impact and results of further investments in our business&#59; the company's future potential growth in 2021&#59; and the 2021 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen&#8217;s business, including, without limitation&#58; the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving our tests&#59; the company&#8217;s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community&#59; the company&#8217;s ability to successfully execute on its business strategy, including its promotion efforts for SIMPONI&#174;&#59; third party payers not providing coverage and adequate reimbursement for the company&#8217;s testing products or promoted therapeutics&#59; the company&#8217;s ability to obtain and maintain intellectual property protection for its testing products&#59; regulatory developments affecting the company&#8217;s business&#59; and other risks described in the company&#8217;s prior press releases and the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including under the heading &#8220;Risk Factors&#8221; in the company&#8217;s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">CONTACTS&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investors</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Westwicke Partners</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mike Cavanaugh</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Mike.Cavanaugh&#64;westwicke.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">646.677.1838</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exagen Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kamal Adawi, Chief Financial Officer</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">kadawi&#64;exagen.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">760.477.5514</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibf26c0325a5f4f0cbb59d835e5ae069c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,587&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,584&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,711&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,545&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,040&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,626&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,403&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,154&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,805&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,567)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,221)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(645)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(631)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,209)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,681)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,209)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,563)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,943,237&#160;</font></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,595,715&#160;</font></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibf26c0325a5f4f0cbb59d835e5ae069c_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,050&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,221&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,910&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,098&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,159&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,369&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,517&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,378&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,522&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,375&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,170&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,014&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,714&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,757&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,884&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,771&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,864&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,659&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">948&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,052&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,536&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $0.001 par value&#59; 10,000,000 shares authorized, no shares issued or outstanding at March&#160;31, 2021 and December 31, 2020</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $0.001 par value&#59; 200,000,000 shares authorized at March&#160;31, 2021 and December 31, 2020&#59; 16,925,680 and 12,652,308 shares issued and outstanding at March&#160;31, 2021 and December 31, 2020, respectively</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288,951&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223,115&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(187,498)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181,289)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,470&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,839&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,522&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,375&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8H# 2(  A$! Q$!_\0
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M&K]!J93POD--+&RYZCZ:W]4ELO7Y,^@AF7$6=5&\*N2'R2]&WN_3YGS9I?\
MP<I_\%';#Q7=>(;JV^'][9W"XBT&Z\,2K:6W&,HT=PDY]?GE;D^G%>Q? /\
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MG_"-Z]?:/'JEK8_\(WJ5YYEH\LL2R;[6VE09>"5=I8,-N2,$$^^5^#?_  =
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M+VRG5F6>>%0FVV<$AB<E>""2/L[_ (.NCE_@+C^[XH_]Q-?G3^PC^PC\7O\
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M4UZVMYNW8^1XLR^%;!_68KWX;VZIZ6?I>_WGE/\ P:_$_P##?WBS_LD.H?\
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MN($3Q37L=TDN&*O:KM )#I_1![&MN-LSG"K#+Z+M&*3:6E^R]$E?MKY&7".
MC.G+&U%>3;2O^+]6].^@M%%%?GY]R&>:Y7XQ_!SX:?M _#'6O@Y\8O!]GKWA
MO7[-K;5-+O%)25,@A@00T<B,%=)$(>-T5T9652.JH&?6G&4H24D[-:IKH1.$
M:D7&2NF?RM?MU_L<^/\ ]@_]I;7OV=/'M]_:']F^7<Z-KT>GRV\.L:?,NZ&Y
MC60?[T<@5G1)H9HQ(_EEC[#_ ,$%.?\ @K'\*/\ >US_ -,-_7W'_P '2_P&
M\/WOPD^&G[3EL;.WU32_$DWA>\6/3$^T7]O=6\MW#ON 0VRW:SGV1$,,WLC
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MH$%I-JWC'5M/\G[19Z;!M5C$)6 +R3206ZL%D,9N!(8W2-UK^ESX0?"'X;?
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M /"@U3_Y74?\0O\ ^W[_ -%8^$?_ (4&J?\ RNK]Y/PHQ[5\O_KAGG\R_P#
M5_D?2?ZIY3VE]Y^#?_$+_P#M^_\ 16/A'_X4&J?_ "NH_P"(7_\ ;]_Z*Q\(
M_P#PH-4_^5U?O)CVHQ[4?ZX9Y_,O_ 5_D'^J>4]I?>?@W_Q"^_M^?]%:^$7_
M (4&J_\ RNH_XA?OV_?^BL_"+_PH-5_^5U?O'D^E<MX@^.'P8\(ZO-X>\6?%
MOPQI>H6^W[18ZAK]M#-%N4,NY'<,,J0PR.00>]5'B[/I.T9)_P#;J(EPOD\=
M9)K_ +>/SW_X(V_\$;/VGO\ @GK^T_KGQJ^-7C?P+J>EZEX%NM%M[?POJE[-
M<"XDO;*=699[2%0FVW<$AB<E>""2/DS_ (.@"?\ AO[PG_V2+3__ $Z:I7[H
M^%O&?A'QSIIUOP5XITW6+,2F/[9I=]'<1!P 2NZ,D9&1QG/(K\+_ /@Z!R/V
M_O"?_9(=/_\ 3KJE=G#>.Q68<31K5_BLUM;9=CDSS!8? </NG0^&Z>]]S[ _
MX->?^3"?&'_97M0_]-6EU^DE?FW_ ,&O/_)A/C#_ +*]J'_IJTNOTDKP<_\
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MZNG>$_$VL*=OB2$K^X@GN.GVT$&(-)M-P?*&Z6>1M_U/_P %,O\ @F/\*O\
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MK>*,/!YL[1EHT!G&U%S'N:?[*_X)B_\ !,?2/V7])M_C-\9+&WOOB+?6Y\F
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MG]E4T?*_+3T6AT^VI:KF6F^JT.SS35('%?)?[ ?_  4;\&?M'GXV2_$GXY>
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MK,X6-7+$JJLQP. I)X!H+EB\+"RE-*[:5VM6G;OWT]3O#GM16/J_CGP7X?\
M$FD^$-=\6Z;9ZMKGG_V+IMU?)'<7_DH'F\F-B&EV(0S;0=H.3@5@_#_]H[X
M_%?7)/#/PQ^-GA/Q%J$<#3R6.B>(;:ZE6($ R%8G9@H+*"V, L/44!+&86-1
M0E.*E>R5U=NR=K=[-?>CMJ***#H/S1_9_N_^"A7Q-_;/_:F_:8_8HT;X.6NF
MZM\3X?!.K67Q0U+59)DNO#EDEHMQ"+&$+Y<PG\PJS%@?D_AWO<_:1\ ?M?\
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M6PIWH&0X#DCSNIXM6IF6%SZM7AA95%.,(QDG!15G)N_-)26LM;1=TE:YY/\
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M)GPQ^-NF^(H)/"?PI^/SVOA_QW>7PGO'\$M?S:<[O(1N"OYBPM%&JJ888B$
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M\;X(-:=CGCD.(I2K4'3E)2M&,KP:Y>5+5RO)-.[>C;?O6=V>,ZQX+UG]I/\
M;!^"'P4_:<T'S-8\!_!N?Q3XNADFC:/5KZ[-O8S6DJ6Y6,1++&[N%+PS*QB*
M&,G=H?MR?L^?L_\ P=UGX)^(/A?\&O#?AO5+CX]>&[9;[P]H-M9R/&SRLT;O
M%&K,A"Y*YP652>E?0_P]^!VL>#OV@O'WQQU7Q_)JD/C&RTBTTO1YK';_ &)!
M913!HEE\QO,626>24@*@5F/WLYI_Q3^"6K_$WXM_#OQ]+XTCMM'\#:K>ZE>>
M')M)2<:I=26<EM;S><6!@,'G2N,*P8OV*JP7?U.G_5^3P-5SIWJSJ+5\KDHI
MQ@I7NEI"*EI9]+7/0H\[1S_"*-C?\]#7&^#/ 'CSP_\ %OQEXZU[XKW.K:+X
M@73QH'A>2Q$<>@_9X62;9)O/FF9V$A)52NT#YA@CM*9]?1E*I3O4BTTVK-K9
M.R>CMJM5UUUU"BBBDSH74****& 4444 ^H4444?:0+J%%%% 1"BBB@)!1110
M'0****74.C"BBBJ[@@HHHIQV8=&%%%%'V@"BBBIZ"^R%%%% PHHHH#J@HHHH
M#N%%%% !1110+N%%%% SR_\ ;;_Y,[^*?_9.]:_]()J;^P__ ,F;_"O_ +)[
MHW_I##110OA/!_YJ9?\ 7I_^E(]2HHHH/H.P4444$A1110 4444!]H****"N
(H4444&<C_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
